Related Experiment Video
Updated: Jul 8, 2026
Large Scale Zebrafish-Based In vivo Small Molecule Screen
Published on: December 30, 2010
Development of an in vitro reproductive screening assay for novel pharmaceutical compounds
Vicki Edwards1, Elda Markovic, Janis Matisons
1Department of Medical Biotechnology, School of Medicine, Flinders University, GPO Box 2100, Adelaide, SA 5001, Australia. edwa0223@flinders.edu.au
Abstract:
An in vitro reproductive cell-based toxicity assay was developed using MLTC-1 (murine Leydig tumour cell line) in order to examine the reproductive toxicity of two novel nanopharmaceutical compounds, namely ethylene glycol mono allyl ether and poly(ethylene glycol) octa-functionalized polyhedral oligomeric silsesquioxane. Three commonly used cytotoxicity assays, namely the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide], MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] and Crystal Violet assays, were compared, and the MTT assay proved to be the most accurate and reproducible for the MLTC-1 cell line. The doubling rate of the MLTC-1 cells was 30+/-3.5 h and the optimal seeding density for the MTT assay was 20000 cells per well, and the optimized MTT assay utilized a 4 h cell adherence followed by incubation with 0.5 mg/ml MTT for 1 h. The intra- and inter-assay CV (coefficient of variation) values were 12.3 and 11% respectively. MLTC-1 cells only produce the reproductive hormone progesterone in response to hCG (human chorionic gonadotropin), which stimulated progesterone production dose-dependently from 0 to 100 m.i.u. (milliinternational units)/ml (2706+/-1118 ng/ml). H(2)O(2) as a negative control killed 100% of cells at 1000 microg/ml. The two nanopharmaceutical compounds were cytotoxic at concentrations > or =0.1 microg/ml, but hCG decreased cytotoxicity to > or =1000 microg/ml (P<0.001). hCG-stimulated progesterone synthesis afforded some protection against the cytotoxic effects of the two novel nanotechnology compounds; therefore doses < or =100 microg/ml and an exposure period of 1 h would be recommended for testing in in vivo animal reproductive assays.
Insights
A new in vitro assay using MLTC-1 cells and the MTT assay was developed to test nanopharmaceutical reproductive toxicity. Human chorionic gonadotropin (hCG) protected cells from nanopharmaceutical compounds, suggesting its use in future reproductive toxicity testing.
Area of Science:
- Reproductive toxicology
- Nanopharmaceutical safety assessment
- In vitro assay development
Background:
- Assessing the reproductive toxicity of novel nanopharmaceuticals is crucial for human health.
- Existing in vitro assays require optimization for specific cell lines and compound types.
- Murine Leydig tumor cells (MLTC-1) are a relevant model for studying reproductive hormone production.
Purpose of the Study:
- To develop and optimize an in vitro reproductive cell-based toxicity assay using MLTC-1 cells.
- To evaluate the reproductive toxicity of two novel nanopharmaceutical compounds.
- To compare the efficacy of MTT, MTS, and Crystal Violet cytotoxicity assays for MLTC-1 cells.
Main Methods:
- Developed an in vitro assay using MLTC-1 cells, optimizing seeding density and incubation times.
- Compared MTT, MTS, and Crystal Violet assays, identifying MTT as the most reproducible.
- Utilized human chorionic gonadotropin (hCG) to stimulate progesterone production and assess its protective effects against nanopharmaceutical compounds.
Main Results:
- The MTT assay was determined to be the most accurate and reproducible for MLTC-1 cells.
- MLTC-1 cells produced progesterone dose-dependently in response to hCG.
- The novel nanopharmaceutical compounds exhibited cytotoxicity at concentrations ≥0.1 µg/ml, which was significantly reduced by hCG (P<0.001).
Conclusions:
- An optimized MTT-based in vitro assay using MLTC-1 cells is suitable for reproductive toxicity testing.
- hCG-stimulated progesterone synthesis offers partial protection against the cytotoxic effects of the tested nanopharmaceuticals.
- Recommended doses ≤100 µg/ml and a 1-hour exposure period for future in vivo animal reproductive assays.
